The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers to Support Therapeutic Trials Program, 2023Analyzing the Aggregation Properties of Alpha-synuclein in Different Genetic Subtypes of Parkinson’s Disease
Study Rationale: Abnormal clumping of alpha-synuclein appears to be an important cause for the death of dopamine cells in Parkinson disease (PD). Recent studies discovered that small amounts of tiny...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Inhibiting Programmed Cell Death to Reduce Axonal Degeneration and Brain Inflammation in Parkinson's Disease
Study Rationale: The degeneration of neuronal axons is an early pathological feature of Parkinson’s disease (PD) and an attractive target for therapeutic intervention. We have demonstrated that a...
-
Research Grant, 2023Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson’s Disease: Phase 2a Double-Blind, Randomized Controlled Trial
Study Rationale: Chronic neuroinflammation plays a critical role in the development and progression of Parkinson’s disease (PD). Neuroinflammation damages the brain microenvironment, disrupts the...
-
Research Grant, 2023Non-Invasive Method for Recovering Protein Biomarkers in Parkinson’s Disease
Study Rationale: There is a need for simple methods to improve the diagnosis of Parkinson’s disease (PD) before individuals ever experience symptoms. Focused ultrasound technology can alter the walls...
-
Biomarkers to Support Therapeutic Trials Program, 2023Using the Chemical Modification of Alpha-synuclein to Define Disease State and Facilitate Patient Stratification in Parkinson’s Disease
Study Rationale: Novel disease-modifying treatments for Parkinson’s disease (PD) are urgently needed as the prevalence of the disease is increasing and no cure is available. At this point, we have...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Dopamine D1 Receptor for a Treatment of Parkinson’s Disease with Minimal L-DOPA-induced Dyskinesia
Study Rationale: L-DOPA is the primary drug used for treating the mobility loss that occurs in Parkinson’s disease (PD) due to decreases in dopamine. Although L-DOPA enhances mobility, chronic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.